MaxCyte stock fell 3.67 percent on October 7

Published on 10/08/2026 at 05:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

MaxCyte stock posted USD 7.271 million in second-quarter revenue, down 15 percent year over year. Fiscal 2026 guidance stayed at USD 30 million to USD 32 million.

MXCT, US57777K1060, Illustration mit AI erstellt.

MaxCyte stock (ISIN US57777K1060) was last at USD 1.050 on Nasdaq on October 7, 2026 at 3:59 p.m. ET, down 3.67 percent from USD 1.090. The company enters its next reporting checkpoint with fiscal 2026 revenue guidance of USD 30 million to USD 32 million.

Revenue fell in the second quarter

According to Investing.com, MaxCyte generated USD 7.271 million in second-quarter 2026 revenue, down 15 percent from the year-earlier period. Adjusted EPS was negative USD 0.08, matching the published forecast.

The same report said gross margin fell to 77 percent from 82 percent a year earlier as product mix changed. Operating figures from the quarter therefore point to a business still dependent on a recovery in partner activity rather than on margin expansion alone.

Analyst targets remain far higher

The analyst consensus published by Investing.com is Strong Buy, based on six analysts, with five Buy ratings and one Hold rating. The average 12-month target is USD 4.108, while the high and low targets are USD 5.00 and USD 2.43.

Against the USD 1.050 Nasdaq price on October 7, 2026, the average target lies 291.24 percent above the price. That gap is a market expectation, not a reported company result, and the stock's 52-week range of USD 0.643 to USD 1.865 shows how far the current quote sits below its yearly high.

Cell engineering remains the core

MaxCyte's investor-relations materials describe the ExPERT platform as a cell-engineering system supporting cell therapy research, development and commercialization. The platform includes instruments, processing assemblies and software protocols for research and biomanufacturing applications.

On September 23, 2026, MaxCyte announced Sidharth Kapileshwar as chief corporate development officer. His remit includes corporate development, strategy and innovation, areas that connect the platform business with the company's effort to broaden pharmaceutical partnerships.

Market value stays near USD 110 million

MaxCyte's market capitalization was USD 109.9 million on October 7, 2026. The combination of a USD 1.050 quote, USD 30 million to USD 32 million revenue guidance and a USD 4.108 consensus target leaves the next earnings update as the clearest scheduled test of the recovery case.